{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-004066","form_type":"8-K","ticker":"PALI","cik":"0001357459","company_name":"PALISADE BIO, INC.","filed_at":"2024-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.938919+00:00","generated_at":"2026-06-06T15:47:39.720118+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Palisade Bio reports positive preclinical data for PALI-2108 UC therapy; Phase 1 planned for 2024","bullets":["PALI-2108 showed colon-selective bioactivation with colon/plasma AUC ratio >200.","In DSS-induced UC mouse model, significant reduction in disease activity index over time.","No CNS toxicity or emesis observed in dogs at effective doses.","Company advancing PALI-2108 toward Phase 1 clinical study, expected to start in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-004066","json":"https://secwatch.observer/filing/0001493152-24-004066.json","markdown":"https://secwatch.observer/filing/0001493152-24-004066.md","text":"https://secwatch.observer/filing/0001493152-24-004066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/0001493152-24-004066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1357459/000149315224004066/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T15:47:39.720118+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}